Sequence-defined phosphoestamers for selective inhibition of the KRASG12D/RAF1 interaction†
Bini Claringbold, Steven Vance, Alexandra R. Paul, James Williamson, Michelle D. Garrett, Christopher J. Serpell · 2024
Read Sequence-defined phosphoestamers for selective inhibition of the KRASG12D/RAF1 interaction† by Bini Claringbold, Steven Vance, Alexandra R. Paul, James Williamson, Michelle D. Garrett, Christopher J. Serpell (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11588021.txt.
Description
Bini Claringbold, Steven Vance, Alexandra Paul, James Williamson, Michelle Garrett, and Christopher Serpell published a 2024 chemistry paper on synthetic chains that block a notorious cancer driver. RAS proteins are the most mutated in cancer, yet they resist drug design. Blocking RAS from its partner RAF is a classic hard problem in protein interaction targeting.
The team adapted DNA synthesis chemistry to build phosphoestamers, sequence defined chains from non DNA building blocks. Their library held nearly a million variants. A bead sorting screen fished out chains that stop the most common RAS mutant from binding RAF. Mass spectrometry read the winners' sequences. Follow up tests confirmed real inhibition at useful strength. The approach offers custom sized molecules for surfaces that small drugs cannot grip.
Catalog record
| CREATOR | Bini Claringbold, Steven Vance, Alexandra R. Paul, James Williamson, Michelle D. Garrett, Christopher J. Serpell |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |